Harrow (HROW) announced leadership changes at its wholly-owned subsidiary, ImprimisRx. Frank Mullery has been appointed as CEO and Bridseida Cruz has been appointed as Head of Quality of ImprimisRx. Most recently, Mullery served as President of Sintetica US, where he spearheaded the creation of the company’s U.S. subsidiary – taking it from concept to full commercialization, while successfully launching its first five sterile injectable products. Cruz is an executive with over 25 years of experience leading quality and operations in 503B outsourcing, pharmaceutical, and medical device organizations.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HROW:
- Harrow price target raised to $74 from $70 at B. Riley
- Harrow price target raised to $70 from $42 at Lake Street
- Harrow Health Secures New $40 Million Credit Facility
- Harrow Health’s Promising Growth Trajectory: Buy Rating Supported by Strategic Initiatives and Product Expansion
- Harrow Health’s Promising Growth Trajectory: Analyst Recommends ‘Buy’ Amid Strategic Revenue Projections and Product Enthusiasm